We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters to the Editor |

Suicide Risk and Efficacy of Antidepressant Drugs—Reply

Robert D. Gibbons, PhD; C. Hendricks Brown, PhD; Kwan Hur, PhD; John M. Davis, MD; J. John Mann, MD
JAMA Psychiatry. 2013;70(1):123-125. doi:10.1001/jamapsychiatry.2013.758.
Text Size: A A A
Published online


In reply

We appreciate Dr Carroll's interest in our article. Dr Carroll states that (1) study LYAQ included atomoxetine with and without fluoxetine in patients with attention-deficit/hyperactivity disorder, (2) less than half of the patients in study LYAQ had major depressive diagnoses, and (3) pretreatment depression scores in study LYAQ matched posttreatment scores in other youth studies, concluding that inclusion of LYAQ “invalidates” our aggregate analysis. Dr Carroll is mistaken. We based our inclusion criteria on all fluoxetine monotherapy vs placebo randomized controlled trials. The first 2 active treatment visits did not include atomoxetine and our analysis of the data from this study was restricted to this period before atomoxetine treatment (days 1-42 postbaseline depending on the subject). Furthermore, although patients in this study had comorbidities including attention-deficit/hyperactivity disorder, the majority (81%) of patients had a depressive disorder. Our statistical approach directly incorporates study-to-study variability in baseline severity and background incidence rate of suicidal events, as well as variability in rates of change over time. As such, our inclusion of this study was scientifically appropriate and in no possible way biased or invalidated our overall conclusion and avoided cherry-picking studies to be included in the analyses.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





January 1, 2013
Bernard J. Carroll, MB, BS, PhD, FRCPsych
JAMA Psychiatry. 2013;70(1):123-125. doi:10.1001/jamapsychiatry.2013.756.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

4 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.